Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

Abstract Background Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-MET and Vascular Endothelial Growth Factor Receptor...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Francesca Corti, Maria Pia Brizzi, Vito Amoroso, Dario Giuffrida, Francesco Panzuto, Davide Campana, Natalie Prinzi, Massimo Milione, Tommaso Cascella, Carlo Spreafico, Giovanni Randon, Simone Oldani, Rita Leporati, Giulia Scotto, Iolanda Pulice, Benedetta Lombardi Stocchetti, Luca Porcu, Jorgelina Coppa, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-09-01
coleção:	BMC Cancer
Assuntos:	Neuroendocrine tumors Lanreotide Cabozantinib Somatostatin analogs Tyrosine kinase inhibitors Clinical trial
Acesso em linha:	https://doi.org/10.1186/s12885-023-11287-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!